San Diego, CA – Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking

Salt Lake City, Utah. Carterra® Inc., the world leader in high-throughput antibody screening and characterization, has announced the availability of a highly accurate assay for simultaneously

University of California San Francisco (UCSF) uses Phenoptics™ platform to help with biomarker discovery Akoya, UCSF and the I-SPY TRIAL consortium collaborate to discover and

New capacity will serve unmet need in COVID-19 testing infrastructure CARLSBAD, CA – Argonaut Manufacturing Services, a contract manufacturing organization (CMO) serving the life sciences,

The assay is intended to aid in the diagnosis of and identification of carriers for spinal muscular atrophy (SMA) AUSTIN, Texas–(BUSINESS WIRE)– Asuragen, Inc., a

High-density EEG complements Magstim’s Transcranial Magnetic Stimulation Technology Driving Innovation MINNEAPOLIS, Minn. & Carmarthenshire, UK — (July 2, 2020) – Magstim, the global leader in Transcranial

Gaithersburg, MD, and Vancouver, Canada – Sirnaomics Inc. (Sirnaomics) and Precision NanoSystems Inc. (PNI) jointly announced a partnership on the development and manufacture of the

Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced the launch of the iPLEX® Pro SARS-CoV-2 Panel for qualitative

MOUNTAIN VIEW, California, June 2, 2020  – Specific Diagnostics today announces that the National Institute for Allergy and Infectious Disease (NIAID) has awarded a second

– CanSinoBIO will license in Precision NanoSystems’ proprietary RNA vaccine platform technology – Precision NanoSystems will lead RNA vaccine formulation development – CanSinoBIO will lead

Additional Resources Will Support Product Development and Expansion of Manufacturing Capabilities   Sacramento, Calif.—(May 19, 2020)—Nivagen Pharmaceuticals, Inc. (“Nivagen”), a specialty pharmaceuticals company, announced the

MADISON, WI–Nimble Therapeutics, Inc. today announced a collaboration with Roche Diagnostics to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro